Nuo Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AURX research report →
Range $3 – $3
Price Chart
About the company
Nuo Therapeutics, Inc. operates as a regenerative medicine company, specializing in the development, commercialization, and marketing of advanced cell-based technologies. These solutions are engineered to leverage the human body's inherent capacity for natural healing, with a primary focus on the United States market.
- CEO
- David E. Jorden
- IPO
- 2017
- Employees
- 10
- HQ
- Houston, TX, US
Get TickerSpark's AI analysis on AURX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $62.93M
- P/E
- -31.10
- Fwd P/E
- 130.00
- PEG
- -1.35
- P/S
- 12.10
- P/B
- -40.99
- EV/EBITDA
- -41.03
- Div Yield
- 0.00%
- Gross Margin
- 64.11%
- Op Margin
- -33.32%
- Net Margin
- -38.70%
- ROE
- 187.41%
- ROIC
- -153.00%
Latest fiscal year · YoY change
- Revenue
- $3.31M+142.7%
- Gross Profit
- $2.22M+108.8%
- Op Income
- $-2,516,649
- Net Income
- $-2,512,216-8.1%
- EPS
- $-0.05-3.7%
- OCF Growth
- +61.2%
- FCF Growth
- +52.2%
- 52W High
- $2.92
- 52W Low
- $0.77
- 50D MA
- $1.12
- 200D MA
- $1.30
- Beta
- -104.09
- RSI (14)
- 63
- Avg Volume
- 2.98K
No earnings-call transcripts are available for AURX yet.
- Free Float
- 41.8%
- Shares Outstanding
- 48.41M
- Float Shares
- 20.23M
of shares held by institutions
1 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Ancora Advisors, LLC | 4.70K | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 6, 26 | Pittman Scott M. | other | 4,500 |
| Oct 6, 26 | Pittman Scott M. | other | 458 |
| Aug 28, 26 | JORDEN DAVID EMERSON | buy | 7,984 |
| Aug 27, 26 | JORDEN DAVID EMERSON | buy | 789 |
| Aug 28, 26 | JORDEN DAVID EMERSON | other | 7,984 |
| Aug 27, 26 | JORDEN DAVID EMERSON | other | 789 |
| Jun 29, 26 | CLAUSEN PETER | other | 65,000 |
| Jun 30, 26 | JORDEN DAVID EMERSON | other | 162,500 |
| Jun 30, 26 | JORDEN DAVID EMERSON | other | 160,892 |
| Jun 29, 26 | JORDEN DAVID EMERSON | other | 125,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AURX coverage
Recent articles, reports, and earnings notes.
No research on AURX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AURX report →Nuo Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
globenewswire.com · Aug 17
Nuo Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
globenewswire.com · May 14
Nuo Therapeutics Announces Exclusive Private Label Distribution Agreement with Smith+Nephew
globenewswire.com · Apr 29
Nuo Therapeutics and PAM Health Partner to Advance Access to Regenerative Wound Healing Therapies
globenewswire.com · Apr 17
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.